Advertisement Aurigene, Pierre Fabre enter into licensing deal for new cancer therapeutic in immuno-oncology - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Aurigene, Pierre Fabre enter into licensing deal for new cancer therapeutic in immuno-oncology

French pharmaceutical firm Pierre Fabre and Indian biotech company Aurigene have entered into a collaborative license, development and commercialization agreement granting Pierre Fabre global worldwide rights (excluding India) to a new immune checkpoint modulator, AUNP-12.

Compared to other molecules currently in development in the immune therapy cancer space, AUNP-12 provides a breakthrough mechanism of action in the PD-1 pathway.

AUNP-12 is the only peptide therapeutic in this pathway and could provide more effective and safer combination opportunities with emerging and established treatment regimens.

As part of the deal, Aurigene will receive an upfront payment from Pierre Fabre and will also receive additional milestone payments based upon the continued development, regulatory progresses and commercialization of AUNP-12, which will be in development for several cancer indications.

Aurigene CEO CSN Murthy said the company is happy that Pierre Fabre see the PD-1 program as a strategic asset in their portfolio.

"Overall, the deal structure, in line with the financial terms that have been seen in this space, demonstrate the importance that Pierre Fabre attach to the program," Murthy said.

Aurigene senior vice president of Research Murali Ramachandra said,"The plans that Pierre Fabre have detailed for the development of this differentiated asset highlight the long-term opportunities for this novel cancer therapeutic."

Pierre Fabre CEO Bertrand Parmentier said, "This agreement, in the field of oncology, is fully consistent with our vision to build Pierre Fabre’s future in prescription drugs, from a combination of cutting-edge internal R&D capabilities and license partnerships with innovative biotech companies like Aurigene."